{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:18Z","timestamp":1792787898264,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-044"],"award-info":[{"award-number":["2022-PUMCH-B-044"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071841"],"award-info":[{"award-number":["82071841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare and rank antihypertensive agents based on their urate-lowering effects in patients with hypertension and hyperuricemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, the Chinese National Knowledge Infrastructure, and the Wanfang databases for eligible trials published up to September 2023. Randomized controlled trials that directly compared different antihypertensive agents in hypertensive patients with hyperuricemia were included. Pairwise and network meta-analyses were conducted using odds ratios and weighted mean differences with 95% confidence intervals. The surface under the cumulative ranking area (SUCRA) was used to rank the efficacy of the antihypertensive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 172 trials involving 16,226 hypertensive patients with hyperuricemia were included in the final analysis. According to SUCRA values, losartan plus amlodipine (SUCRA: 96%), valsartan plus amlodipine (SUCRA: 90%), and allisartan (SUCRA: 90%) showed relatively superior effects in reducing serum uric acid levels. Additionally, irbesartan plus amlodipine (SUCRA: 94%), losartan plus amlodipine (SUCRA: 92%), and losartan (SUCRA: 84%) were associated with higher effective rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on the only available eligible evidence, the combination of losartan and amlodipine was the optimal dual therapy for Chinese patients with hypertension and hyperuricemia, while allisartan and losartan were the most effective monotherapies for lowering serum uric acid. These findings are not generalizable to non-Chinese populations, reflecting a gap in global evidence rather than intentional study scope restriction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-05339-7","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:37:42Z","timestamp":1764686262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Juan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"5339_CR1","first-page":"209","volume":"34","author":"SS Hu","year":"2019","unstructured":"Hu SS, Gao RL, Liu LS. Summary of China cardiovascular disease report 2018. Chin Circul J. 2019;34:209\u201320.","journal-title":"Chin Circul J"},{"issue":"6","key":"5339_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of Population-Based studies from 90 countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"issue":"1","key":"5339_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jch.13136","volume":"20","author":"A Maloberti","year":"2018","unstructured":"Maloberti A, Maggioni S, Occhi L, Triglione N, Panzeri F, Nava S, et al. Sex-related relationships between uric acid and target organ damage in hypertension. J Clin Hypertens (Greenwich). 2018;20(1):193\u2013200.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"5339_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/HJH.0000000000001908","volume":"37","author":"P Redon","year":"2019","unstructured":"Redon P, Maloberti A, Facchetti R, Redon J, Lurbe E, Bombelli M, et al. Gender-related differences in serum uric acid in treated hypertensive patients from central and East European countries: findings from the blood pressure control rate and cardiovascular risk profile study. J Hypertens. 2019;37(2):380\u20138.","journal-title":"J Hypertens"},{"issue":"1","key":"5339_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/atm-20-3458","volume":"9","author":"J Liu","year":"2021","unstructured":"Liu J, Chen L, Yuan H, Huang K, Li G, Sun N, et al. Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): a nationwide cross-sectional study. Ann Transl Med. 2021;9(1):27.","journal-title":"Ann Transl Med"},{"issue":"7","key":"5339_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125(7):679\u2013e687671.","journal-title":"Am J Med"},{"issue":"1","key":"5339_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/HJH.0b013e328365b916","volume":"32","author":"AF Cicero","year":"2014","unstructured":"Cicero AF, Salvi P, D\u2019Addato S, Rosticci M, Borghi C. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella heart study. J Hypertens. 2014;32(1):57\u201364.","journal-title":"J Hypertens"},{"issue":"2","key":"5339_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/BOR.0000000000000033","volume":"26","author":"DI Feig","year":"2014","unstructured":"Feig DI. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr Opin Rheumatol. 2014;26(2):176\u201385.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"5339_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/HJH.0000000000002600","volume":"39","author":"A Maloberti","year":"2021","unstructured":"Maloberti A, Bombelli M, Facchetti R, Barbagallo CM, Bernardino B, Rosei EA, et al. Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the uric acid right for heart health study. J Hypertens. 2021;39(2):333\u201340.","journal-title":"J Hypertens"},{"issue":"12","key":"5339_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1055\/s-0042-113183","volume":"66","author":"S Ueno","year":"2016","unstructured":"Ueno S, Hamada T, Taniguchi S, Ohtani N, Miyazaki S, Mizuta E, et al. Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: Cross-Sectional cohort study. Drug Res (Stuttg). 2016;66(12):628\u201332.","journal-title":"Drug Res (Stuttg)"},{"issue":"4","key":"5339_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/HJH.0000000000000478","volume":"33","author":"Y Fan","year":"2015","unstructured":"Fan Y, Wei F, Lang Y, Wang S. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. J Hypertens. 2015;33(4):681\u20138. discussion 689.","journal-title":"J Hypertens"},{"key":"5339_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"03","key":"5339_CR13","first-page":"61","volume":"27","author":"L Liang","year":"2019","unstructured":"Liang L, Wang J, Li B, Yue X. Comparative analysis of Losartan and Telmisartan in the treatment of hypertension with hyperuricemia. Capital Food Med. 2019;27(03):61\u20132.","journal-title":"Capital Food Med"},{"key":"5339_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"2","key":"5339_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model Estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111\u201325.","journal-title":"Res Synth Methods"},{"issue":"6","key":"5339_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"5339_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"5339_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2288-12-150","volume":"12","author":"L Trinquart","year":"2012","unstructured":"Trinquart L, Chatellier G, Ravaud P. Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol. 2012;12:150.","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"5339_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"4","key":"5339_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"issue":"10","key":"5339_CR21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/ajh.2008.245","volume":"21","author":"T Hamada","year":"2008","unstructured":"Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of Losartan via the Inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008;21(10):1157\u201362.","journal-title":"Am J Hypertens"},{"issue":"1","key":"5339_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1254\/jphs.10064SC","volume":"114","author":"M Nakamura","year":"2010","unstructured":"Nakamura M, Anzai N, Jutabha P, Sato H, Sakurai H, Ichida K. Concentration-dependent inhibitory effect of Irbesartan on renal uric acid transporters. J Pharmacol Sci. 2010;114(1):115\u20138.","journal-title":"J Pharmacol Sci"},{"key":"5339_CR23","first-page":"485","volume":"24","author":"L Jiang","year":"2019","unstructured":"Jiang L, Du GS, Chen RJ. Therapeutic effect of Alisartan ester on mild to moderate hypertension complicated with hyperuricemia. Linan J Emerg Med. 2019;24:485\u20136.","journal-title":"Linan J Emerg Med"},{"key":"5339_CR24","first-page":"1542","volume":"40","author":"GY Lu","year":"2011","unstructured":"Lu GY, Zhang L. Research progress on the interaction between hyperuricemia and metabolic syndrome. Chongqing Med. 2011;40:1542\u20133.","journal-title":"Chongqing Med"},{"key":"5339_CR25","doi-asserted-by":"publisher","first-page":"1159973","DOI":"10.1155\/2023\/1159973","volume":"2023","author":"L Wang","year":"2023","unstructured":"Wang L, Song TT, Dong CW. Association between interactions among ACE gene polymorphisms and essential hypertension in patients in the Hefei Region, Anhui, China. J Renin Angiotensin Aldosterone Syst. 2023;2023:1159973.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"5339_CR26","doi-asserted-by":"publisher","first-page":"7890188","DOI":"10.1155\/2023\/7890188","volume":"2023","author":"H Ahmad","year":"2023","unstructured":"Ahmad H, Khan H, Haque S, Ahmad S, Srivastava N, Khan A. Angiotensin-Converting enzyme and hypertension: A systemic analysis of various ACE Inhibitors, their side Effects, and bioactive peptides as a putative therapy for hypertension. J Renin Angiotensin Aldosterone Syst. 2023;2023:7890188.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"5339_CR27","doi-asserted-by":"publisher","first-page":"4201342","DOI":"10.1155\/2023\/4201342","volume":"2023","author":"D Jiang","year":"2023","unstructured":"Jiang D, Matsuzaki M, Kawagoe Y, Kitamura K, Tsuruda T, Kaikita K, et al. Analysis of mechanisms for increased blood pressure variability in rats continuously infused with angiotensin II. J Renin Angiotensin Aldosterone Syst. 2023;2023:4201342.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"5339_CR28","first-page":"158","volume":"34","author":"X Zhang","year":"2014","unstructured":"Zhang X, Ma L. Curative effect of Irbesartan combined with amlodipine besylate on elderly patients with diabetes mellitus combined with hypertension and hyperuricemia. Chin J Biochem Pharm. 2014;34:158.","journal-title":"Chin J Biochem Pharm"},{"issue":"1","key":"5339_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00050919","volume":"6","author":"GJ Gross","year":"1992","unstructured":"Gross GJ, Pieper GM. Beneficial actions of amlodipine in the multiple-stunned canine myocardium. Cardiovasc Drugs Ther. 1992;6(1):67\u201375.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1\u20133","key":"5339_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejphar.2009.08.021","volume":"620","author":"J Li","year":"2009","unstructured":"Li J, Li QX, Xie XF, Ao Y, Tie CR, Song RJ. Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicin-induced renal tubular toxicity in rats. Eur J Pharmacol. 2009;620(1\u20133):97\u2013104.","journal-title":"Eur J Pharmacol"},{"key":"5339_CR31","first-page":"79","volume":"6","author":"M Nakamura","year":"2014","unstructured":"Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of Irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol. 2014;6:79\u201386.","journal-title":"Clin Pharmacol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05339-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:37:43Z","timestamp":1764686263000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5339"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05339-7","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"856"}}